ES2135476T3 - Utilizacion de remacemida para el tratamiento de la enfermedad de parkinson. - Google Patents

Utilizacion de remacemida para el tratamiento de la enfermedad de parkinson.

Info

Publication number
ES2135476T3
ES2135476T3 ES93911903T ES93911903T ES2135476T3 ES 2135476 T3 ES2135476 T3 ES 2135476T3 ES 93911903 T ES93911903 T ES 93911903T ES 93911903 T ES93911903 T ES 93911903T ES 2135476 T3 ES2135476 T3 ES 2135476T3
Authority
ES
Spain
Prior art keywords
remacemide
parkinson
disease
treatment
conjuction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93911903T
Other languages
English (en)
Inventor
Peter Johnson
Barry Ernest Watkins
Eric William Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Application granted granted Critical
Publication of ES2135476T3 publication Critical patent/ES2135476T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

2-AMINO-N-(1,2-DIFENILO-1-METILETIL) ACETAMIDA (REMACEMIDA) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE ELLA, Y L-DOPA, SE USAN EN CONJUNCION UNA CON OTRA EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON. SE PROPORCIONAN PRODUCTOS FARMACEUTICOS Y FORMULACIONES QUE COMPRENDEN ESTOS AGENTES ACTIVOS.
ES93911903T 1992-05-02 1993-04-30 Utilizacion de remacemida para el tratamiento de la enfermedad de parkinson. Expired - Lifetime ES2135476T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929209599A GB9209599D0 (en) 1992-05-02 1992-05-02 Novel therapy for the treatment of parkinsons disease

Publications (1)

Publication Number Publication Date
ES2135476T3 true ES2135476T3 (es) 1999-11-01

Family

ID=10714969

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93911903T Expired - Lifetime ES2135476T3 (es) 1992-05-02 1993-04-30 Utilizacion de remacemida para el tratamiento de la enfermedad de parkinson.

Country Status (16)

Country Link
EP (1) EP0637956B1 (es)
JP (1) JP3542801B2 (es)
KR (1) KR950701216A (es)
AT (1) ATE181669T1 (es)
CA (1) CA2134783C (es)
DE (1) DE69325512T2 (es)
DK (1) DK0637956T3 (es)
ES (1) ES2135476T3 (es)
GB (1) GB9209599D0 (es)
GR (1) GR3031320T3 (es)
HU (1) HU211305A9 (es)
IL (1) IL105569A (es)
NZ (2) NZ299042A (es)
SG (1) SG49202A1 (es)
WO (1) WO1993021910A1 (es)
ZA (1) ZA933086B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025369A (en) * 1996-05-03 2000-02-15 The Board Of Regents Of The University Nebraska N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
EP2331088A4 (en) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA908490B (en) * 1989-10-27 1991-07-31 Fisons Corp Use of arylalkylamides in the treatment of neurodegenerative diseases
DE3940410A1 (de) * 1989-12-04 1991-06-06 Schering Ag Neue verwendung von nmda-rezeptor-antagonisten

Also Published As

Publication number Publication date
CA2134783A1 (en) 1993-11-11
JP3542801B2 (ja) 2004-07-14
DE69325512T2 (de) 1999-12-16
NZ299042A (en) 2000-07-28
EP0637956B1 (en) 1999-06-30
SG49202A1 (en) 1998-05-18
GB9209599D0 (en) 1992-06-17
WO1993021910A1 (en) 1993-11-11
NZ252728A (en) 1996-11-26
DK0637956T3 (da) 1999-11-22
ZA933086B (en) 1993-11-01
ATE181669T1 (de) 1999-07-15
HU211305A9 (en) 1995-11-28
IL105569A (en) 1997-11-20
DE69325512D1 (de) 1999-08-05
KR950701216A (ko) 1995-03-23
GR3031320T3 (en) 1999-12-31
EP0637956A1 (en) 1995-02-15
JPH07506105A (ja) 1995-07-06
IL105569A0 (en) 1993-08-18
CA2134783C (en) 2002-08-13

Similar Documents

Publication Publication Date Title
MX9307885A (es) Aplicacion de la carbamzaepina y oxcarbazepian para la obtencion de medicamentos para el tratamiento de la enfermedad de parkinson y los sindromes parkinsonianos.
HK1003978A1 (en) Composition for the treatment of schizophrenia
UY26779A1 (es) Prodrogas 3` de 2' -desoxi-b-l-nucleósidos
KR920019342A (ko) 골질환 치료제
PT100199A (pt) Combinacao antiviral de nucleosidos e processo para a sua preparacao
AR019261A1 (es) Cetoazalido de la clase de lactamas de 15 miembros, su uso, procedimiento para prepararlo , y una composicion farmaceutica util para el tratamiento de infecciones bacterianas en seres humanos y animales
KR940018087A (ko) 진통제 및 소염제로서의 6-클로로-5-플루오로-3-(2-테노일)-2-옥신돌-ⅰ-카복스아미드
ES2135476T3 (es) Utilizacion de remacemida para el tratamiento de la enfermedad de parkinson.
ES2115055T3 (es) 1-fenil-2-(2-piridinil)etilamina enantiomera para el tratamiento de trastornos neurodegenerativos.
ITMI910658A0 (it) N-(4,5-diidrossi-e 4,5,8-triidrossi-9,10-diidro-9,10-diosso-2- antracen-il)carbonil) amminoacidi utilizzabili nella terapia delle affezioni osteoarticolari
NO944809L (no) Biologisk aktive ureidoderivater som er nyttig i behandling av lentivirus-indusert sykdom
ES2147576T3 (es) Utilizacion del efaroxan y de sus derivados para la preparacion de un medicamento destinado al tratamiento de la enfermedad de parkinson.
NO20044519L (no) Hyperforinderivater, anvendelse derav samt formuleringer som inneholder dem
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
DE69130235D1 (de) Rezeptor-konjugate zum targeting von arzneiwirkstoffen und anderen wirksubstanzen
CA2170289A1 (en) A method of treating liver disease and like indications with vasodilating agents
ITMI940030A0 (it) Compressa farmaceutica ad eleavata e rapida disponibilita' del principio attivo in essa veicolato
IT1275987B1 (it) Composizione farmaceutica attiva nella cura di affezioni dermatologiche
RU96118559A (ru) Лекарственное средство
TH14332EX (th) อนุพันธ์ของอาร์จีนีน

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 637956

Country of ref document: ES